Abstract
Patients rely on their primary care physician to manage multiple, often chronic medical conditions that require prescription medications. Balancing the risk to benefit of treatments can be challenging and requires that the primary care physician stay abreast of new information regarding risks and benefits. The number of medications with reported adverse effects on skeletal health is expanding. This review focuses on medications recently added to the list of "bad to the bone" drugs and on recent advances in management of glucocorticoid-induced osteoporosis. A practical approach to assessing and managing the skeletal risks is outlined. © 2011 Mayo Foundation for Medical Education and Research.
Cite
CITATION STYLE
Davidge Pitts, C. J., & Kearns, A. E. (2011). Update on medications with adverse skeletal effects. Mayo Clinic Proceedings. Elsevier Ltd. https://doi.org/10.4065/mcp.2010.0636
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.